Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2018 1
2019 1
2020 2
2021 2
2022 1
2023 2
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif AL, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S, Potter N, Sellar R, Taylor T, Zhao R, Russell NH, Wei AH, Dillon R. Othman J, et al. Among authors: mokretar k. Blood. 2024 Jan 25;143(4):336-341. doi: 10.1182/blood.2023021579. Blood. 2024. PMID: 37647641
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, Jain M, Aries J, Cakmak S, Knapper S, Kristensen DT, Murthy V, Galani JZ, Kallmeyer C, Ngu L, Veale D, Bolam S, Orfali N, Parker A, Manson C, Parker J, Erblich T, Richardson D, Mokretar K, Potter N, Overgaard UM, Roug AS, Wei AH, Esteve J, Jädersten M, Russell N, Dillon R. Jimenez-Chillon C, et al. Among authors: mokretar k. Blood Adv. 2024 Jan 23;8(2):343-352. doi: 10.1182/bloodadvances.2023011106. Blood Adv. 2024. PMID: 38039513 Free PMC article.
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, Latif AL, Cahalin P, Aries J, Amer M, Belsham E, Conneally E, Craddock C, Culligan D, Dennis M, Duncan C, Freeman SD, Furness C, Gilkes A, Gkreka P, Hodgson K, Ingram W, Jain M, King A, Knapper S, Kottaridis P, McMullin MF, Mohite U, Ngu L, O'Nions J, Patrick K, Rider T, Roberts W, Severinsen MT, Storrar N, Taylor T, Russell NH, Dillon R. Othman J, et al. Among authors: mokretar k. Leukemia. 2023 Oct;37(10):2066-2072. doi: 10.1038/s41375-023-01994-x. Epub 2023 Aug 9. Leukemia. 2023. PMID: 37558736 Free PMC article.
Recommendations from the AML molecular MRD expert advisory board.
Scott S, Devonshire A, Dillon R, Thiede C, Cross NCP, White HE, Lo Cascio L, Mokretar K, Potter N, Hourigan CS, Radich J, Corner A, Laloux V, Halliday G, Dilks D, Morrison T, Gilmour K, Cartwright A, Whitby L. Scott S, et al. Among authors: mokretar k. Leukemia. 2024 Jul;38(7):1638-1641. doi: 10.1038/s41375-024-02275-x. Epub 2024 May 23. Leukemia. 2024. PMID: 38783160 Free PMC article. No abstract available.
Molecular Monitoring of Chronic Myeloid Leukemia.
Dominy K, Mokretar K, Reid AG, Khorashad JS. Dominy K, et al. Among authors: mokretar k. Methods Mol Biol. 2020;2065:153-173. doi: 10.1007/978-1-4939-9833-3_12. Methods Mol Biol. 2020. PMID: 31578694
The PS4-likelihood ratio calculator: flexible allocation of evidence weighting for case-control data in variant classification.
Rowlands CF, Garrett A, Allen S, Durkie M, Burghel GJ, Robinson R, Callaway A, Field J, Frugtniet B, Palmer-Smith S, Grant J, Pagan J, McDevitt T, McVeigh TP, Hanson H, Whiffin N, Jones M, Turnbull C; CanVIG-UK. Rowlands CF, et al. J Med Genet. 2024 Sep 24;61(10):983-991. doi: 10.1136/jmg-2024-110034. J Med Genet. 2024. PMID: 39227160 Free PMC article.
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
Claudiani S, Mason CC, Milojkovic D, Bianchi A, Pellegrini C, Di Marco A, Fiol CR, Robinson M, Ponnusamy K, Mokretar K, Chowdhury A, Albert M, Reid AG, Deininger MW, Naresh K, Apperley JF, Khorashad JS. Claudiani S, et al. Among authors: mokretar k. Cancers (Basel). 2021 Sep 28;13(19):4863. doi: 10.3390/cancers13194863. Cancers (Basel). 2021. PMID: 34638347 Free PMC article.
16 results